Company Overview of ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead product candidate is NUPLAZID, which completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis; is in Phase II study for Alzheimer’s disease psychosis; and has completed Phase II trial for the treatment of schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
3611 Valley Centre Drive
San Diego, CA 92130
Founded in 1993
Key Executives for ACADIA Pharmaceuticals Inc.
Interim Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Executive Vice President
Total Annual Compensation: $245.6K
Chief Medical Officer and Executive Vice President of Development
Total Annual Compensation: $544.0K
Chief Commercial Officer and Executive Vice President
Total Annual Compensation: $489.6K
Executive Vice President, General Counsel and Secretary
Total Annual Compensation: $457.0K
Compensation as of Fiscal Year 2014.
ACADIA Pharmaceuticals Inc. Key Developments
ACADIA Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 6 15
ACADIA Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported collaborative revenues of $1,000 against $28,000 a year ago. Loss from operations was $39,497,000 against $21,723,000 a year ago. Net loss was $39,378,000 or $0.39 per share basic and diluted against $21,495,000 or $0.22 per share basic and diluted a year ago.
For the six months, the company reported collaborative revenues of $5,000 against $58,000 a year ago. Loss from operations was $80,049,000 against $39,681,000 a year ago. Net loss was $79,753,000 or $0.80 per share basic and diluted against $39,323,000 or $0.41 per share basic and diluted a year ago.
ACADIA Pharmaceuticals Inc. Announces Publication of New Data from its Ongoing Open-Label Safety Extension Study with NUPLAZID in Patients with Parkinson’s Disease Psychosis
Aug 6 15
ACADIA Pharmaceuticals Inc. announced the publication of new data from its ongoing open-label safety extension study, the -015 Study, with NUPLAZID™ in patients with Parkinson’s disease psychosis (PDP) in the July 31 online issue of the Journal of the American Medical Directors Association (www.jamda.com). This is the first published report evaluating the long-term impact of antipsychotics on mortality and serious adverse events in patients with PDP. Currently marketed antipsychotics are not approved for PDP and have a black box warning for use in elderly patients with dementia due to increased mortality and morbidity. NUPLAZID was granted Breakthrough Therapy designation from the FDA in 2014 and has the potential to be the first drug approved for the treatment of PDP in the United States. In the -015 study, all patients received NUPLAZID (40 mg). Of 423 patients assessed, 357 received NUPLAZID only, while 66 patients received a currently marketed antipsychotic prescribed by their physician at some point during the study in addition to NUPLAZID. The two groups were well matched at baseline with regard to age (mean of 71-72 years) and other demographic and baseline variables. In a post-hoc analysis, there was a significant increase in the mortality rate of patients who received concurrent treatment with a currently marketed antipsychotic (18.8 deaths per 100 person-years since the first concurrent antipsychotic dose) compared to those who received NUPLAZID only (4.5 deaths per 100 person-years). There also was a significant increase in treatment emergent serious adverse events in patients who received concurrent treatment with a currently marketed antipsychotic (52.5 first-occurrence events per 100 person-years since the first concurrent antipsychotic dose) compared to those who received NUPLAZID only (17.8 first-occurrence events per 100 person-years). NUPLAZID is ACADIA’s proprietary small molecule that is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors that play an important role in psychosis. ACADIA has reported positive Phase III trial results with NUPLAZID, which has the potential to be the first drug approved in the United States for psychosis associated with Parkinson’s disease. NUPLAZID is administered orally once-a-day. ACADIA discovered NUPLAZID and holds worldwide rights to this new chemical entity. The trade name NUPLAZID has been provisionally accepted by the FDA.
ACADIA Pharmaceuticals Inc. Announces Management Appointments
Aug 5 15
ACADIA Pharmaceuticals Inc. announced the following senior management appointments: James A. Nash, Senior Vice President, Technology Development and Operations, Ryan E. Brown, Vice President, Chief Compliance Officer, Fred W. Manak, Jr., Vice President, Access and Reimbursement and BobMischler, Vice President, Strategy and Business Development. Mr. Nash joins ACADIA as Senior Vice President, Technology Development and Operations. In this new role, he is responsible for pharmaceutical development, manufacturing and GMP quality assurance. Mr. Nash brings over 30 years of executive level experience in these key technical functions. Prior to joining ACADIA, Mr. Nash served as Vice President, Technology Development and Operations at ViroPharma Inc. from 2008 to 2014, where he established supply chain, quality assurance and process development organizations in a rapidly growing specialty pharmaceutical company and supported the successful launch of Cinryze® for the treatment of hereditary angioedema. Mr. Brown joins ACADIA as Vice President, Chief Compliance Officer. In this new role, he is responsible for developing, implementing, and managing the company’s corporate compliance program to support the planned commercialization of NUPLAZID and other future product opportunities. Mr. Manak joins ACADIA as Vice President, Access and Reimbursement. In this new role, he is responsible for establishing ACADIA’s access and reimbursement strategy to support the planned commercialization of NUPLAZID and other future product opportunities. Mr. Mischler joins ACADIA as Vice President, Strategy and Business Development. In this new role, he is responsible for strategic planning and business development initiatives. Prior to joining ACADIA, Mr. Mischler served as Vice President, Scientific Affairs and Business Development at Ardea Biosciences. Previously, he served as Vice President, Commercial Planning and Analytics at Ardea Biosciences, where he was significantly involved in business development and led commercial activities. Earlier in his career, he worked in various roles focused on product and portfolio strategy at CovX Research LLC, Pfizer Inc. and Eli Lilly and Company. Mr. Mischler received his Bachelor of Science in Biologic Sciences from Indiana University and his Master of Business Administration from the UCLA Anderson School of Management.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|